|
|
 |
|
Viewing report
|
|
|
|
Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
GlobalData, Oct 2011, Pages: 100
Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Major Depressive Disorder (MDD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global MDD therapeutics market, identifying the key trends shaping and driving the global MDD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global MDD therapeutics market was worth $6.9 billion in 2010 and expected it to grow at a compound annual growth rate (CAGR) of 6% over the next eight years to reach $11 billion by 2018. The MDD therapeutics market will witness the patent expiry of Lexapro in 2012, Cymbalta in 2013 and Effexor XR in 2014. However, the launch of new drugs such as Viibryd, LuAA21004, Levomilnacipran (F2695) and Agomelatine (AGO178) in the US, offering better efficacy and safety profiles, along with disease modifying properties, will help to sustain steady and positive growth during the forecast period to 2018.
Scope
The report provides information on the key drivers and challenges of the MDD market. Its scope includes -
- Annualized global MDD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Glutamate receptor which includes glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiators. Seretonin receptor modulators which includes 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT1A receptor agonists and 5-HT3 receptor antagonist. Serotonin and Norepinephrine reuptake inhibitors (SNRIs), triple-reuptake inhibitors, monoamine oxidase (MAO) inhibitors, norepinephrine reuptake inhibitors, sigma receptor agonists, glycine site partial agonist and vasopressin antagonists.
- Analysis of the current and future competition in the global MDD market. Key market players covered are Shire plc, Novartis, Dainippon Sumitomo, Forest Laboratries, H Lundbeck A/S, Eli Lilly and Company, Targacept and Fabre-Kramer.
- An Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics coverage, including strategic competitor assessment, market characterization, unmet needs and the implications for the MDD therapeutics market.
- Analysis of key recent licensing and partnership agreements in the MDD therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global MDD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDD market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global MDD market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
